These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
526 related articles for article (PubMed ID: 25946693)
1. SUBFOVEAL CHOROIDAL THICKNESS CHANGES IN TREATED IDIOPATHIC CENTRAL SEROUS CHORIORETINOPATHY AND THEIR ASSOCIATION WITH RECURRENCE. Kim DY; Joe SG; Yang HS; Lee JY; Kim JG; Yoon YH Retina; 2015 Sep; 35(9):1867-74. PubMed ID: 25946693 [TBL] [Abstract][Full Text] [Related]
2. The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy. Kim DY; Joe SG; Yang SJ; Lee JY; Kim JG; Yoon YH Korean J Ophthalmol; 2015 Jun; 29(3):160-7. PubMed ID: 26028943 [TBL] [Abstract][Full Text] [Related]
3. Choroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathy. Okamoto M; Matsuura T; Ogata N Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):25-32. PubMed ID: 25559505 [TBL] [Abstract][Full Text] [Related]
4. FLAT IRREGULAR PIGMENT EPITHELIUM DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: A Form of Pachychoroid Neovasculopathy? Hwang H; Kim JY; Kim KT; Chae JB; Kim DY Retina; 2020 Sep; 40(9):1724-1733. PubMed ID: 31584559 [TBL] [Abstract][Full Text] [Related]
5. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy. Kim YK; Ryoo NK; Woo SJ; Park KH Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629 [TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. Kim GA; Rim TH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS Eye (Lond); 2015 Jun; 29(6):732-40; quiz 741. PubMed ID: 25952951 [TBL] [Abstract][Full Text] [Related]
7. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858 [TBL] [Abstract][Full Text] [Related]
8. TWELVE-MONTH EFFICACY OF INTRAVITREAL BEVACIZUMAB INJECTION FOR CHRONIC, ATYPICAL, OR RECURRENT CENTRAL SEROUS CHORIORETINOPATHY. Chung YR; Kim JW; Song JH; Park A; Kim MH Retina; 2019 Jan; 39(1):134-142. PubMed ID: 29077604 [TBL] [Abstract][Full Text] [Related]
9. SUBFOVEAL CHOROIDAL THICKNESS AND VASCULAR DIAMETER IN ACTIVE AND RESOLVED CENTRAL SEROUS CHORIORETINOPATHY. Chung YR; Kim JW; Choi SY; Park SW; Kim JH; Lee K Retina; 2018 Jan; 38(1):102-107. PubMed ID: 28106708 [TBL] [Abstract][Full Text] [Related]
10. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. Smretschnig E; Hagen S; Glittenberg C; Ristl R; Krebs I; Binder S; Ansari-Shahrezaei S Eye (Lond); 2016 Jun; 30(6):805-11. PubMed ID: 26965012 [TBL] [Abstract][Full Text] [Related]
11. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289 [TBL] [Abstract][Full Text] [Related]
13. Abnormal choroidal flow on optical coherence tomography angiography in central serous chorioretinopathy. Seo EJ; Um T; Yoon YH Clin Exp Ophthalmol; 2019 May; 47(4):505-512. PubMed ID: 30515936 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal Bevacizumab and Ranibizumab in the Treatment of Acute Central Serous Chorioretihopathy: A Single Center Retrospective Study. Tekin K; Sekeroglu MA; Cankaya AB; Teke MY; Doguizi S; Yilmazbas P Semin Ophthalmol; 2018; 33(2):265-270. PubMed ID: 27841949 [TBL] [Abstract][Full Text] [Related]
15. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Maruko I; Iida T; Sugano Y; Furuta M; Sekiryu T Retina; 2011 Oct; 31(9):1921-7. PubMed ID: 21878850 [TBL] [Abstract][Full Text] [Related]
16. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy. Pryds A; Larsen M Acta Ophthalmol; 2012 Dec; 90(8):738-43. PubMed ID: 21586096 [TBL] [Abstract][Full Text] [Related]
17. Change of regional choroid thickness after reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy. Manabe S; Shiragami C; Hirooka K; Izumibata S; Tsujikawa A; Shiraga F Am J Ophthalmol; 2015 Apr; 159(4):644-51. PubMed ID: 25595669 [TBL] [Abstract][Full Text] [Related]
18. Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy. Kim H; Lee K; Lee CS; Byeon SH; Lee SC Retina; 2015 Mar; 35(3):481-6. PubMed ID: 25313710 [TBL] [Abstract][Full Text] [Related]